Articles

Adjuvant ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease-free survival (IDFS) and overall survival (OS) versus adjuvant trastuzumab in patients with high-risk HER2-positive early breast cancer, according to 7-year follow-up of the phase 3 KATHERINE trial. Read More ›

San Antonio—Dual HER2-directed therapy with tucatinib and trastuzumab emtansine (T-DM1) extended progression-free survival (PFS) compared with T-DM1 alone in patients with previously treated, resectable, locally advanced or metastatic HER2-positive breast cancer. Read More ›

San Antonio—A 9-month twice weekly structured exercise program improved measures of fatigue and quality of life among patients with metastatic breast cancer, according to a randomized controlled trial presented by Anne M. May, PhD, professor, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, at the 2023 San Antonio Breast Cancer Symposium. Read More ›

A new study has revealed some important information about the behavior of one of the most notorious forms of cancer. Pancreatic cancer, the study found, can readily turn to an alternate source of energy to survive when its primary source, the sugar molecule glucose, is in short supply. Read More ›

Life expectancy in the United States is increasing, and parallel to this will be an increase in the number of older adults with cancer. Read More ›

San Diego—Patients with relapsed or refractory acute leukemia with rearrangement in the KMT2Ar gene, an aggressive and difficult-to-treat leukemia, had an overall response rate of 63% when treated with the investigational agent revumenib, according to data from the single-arm pivotal phase 2 AUGMENT-101 study presented by Ibrahim Aldoss, MD, associate professor, Department of Hematology and Stem Cell Transplant, City of Hope National Medical Center, Duarte, California, at the 65th American Society of Hematology Annual Meeting Read More ›

Navigating today’s healthcare system can be challenging for anyone, but for older adults, it can be especially difficult. Read More ›

In 2023, much research has been conducted on the treatment of biliary tract cancer (BTC), with an emphasis on novel targeted therapies and combination strategies. Important advances in treatment for patients with BTC were presented at society conferences such as the American Society of Clinical Oncology (ASCO), ASCO GI, and European Society for Medical Oncology. Read More ›